<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
___________________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
JULY 26, 2000 (JULY 18, 2000)
Date of Report (Date of earliest event reported)
AVAX TECHNOLOGIES, INC.
(Exact name of Registrant as specified in its charter)
DELAWARE 000-29222 13-3575874
(State or other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification Number)
4520 MAIN STREET
SUITE 930
KANSAS CITY, MO 64111
(Address of principal executive offices)
(816) 960-1333
(Registrant's telephone number, including area code)
1
<PAGE>
ITEM 5. OTHER EVENTS
(a) M-VAX-TM- COMMERCIALLY AVAILABLE IN AUSTRALIA.
On July 18, 2000, the Company announced that M-Vax, its autologous
cell vaccine (AC Vaccine-TM-) for the treatment of stage 3 melanoma, is now
commercially available in Australia. The Company currently owns a 65%
interest in the Australian joint venture entity that is marketing M-Vax in
Australia. M-Vax is produced in Australia through a contract manufacturing
agreement with Bioenterprises Pty. Limited.
(b) COMPANY SIGNS PRELIMINARY AGREEMENT TO ACQUIRE GENOPOIETIC S. A.
On July 18, 2000, the Company announced that it had signed an
agreement to acquire Genopoietic S.A. and its corporate affiliates, based in
Paris, France. The transaction is subject to certain closing conditions,
which the parties anticipate will be completed by the end of the summer.
Pursuant to the terms of the agreement, 100% of the outstanding
shares of Genopoietic will be contributed to the Company in exchange for a
combination of common stock of the Company and options to acquire common
stock of the Company. In the aggregate, the shares of the Company's common
stock and options to acquire common stock will not exceed 3,000,000 shares.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
EXHIBITS.
99.1 Press Release dated July 18, 2000 announcing commercialization
of M-Vax in Australia.
99.2 Press Release dated July 18, 2000 announcing Company's
agreement to acquire Genopoietic.
2
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Company has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
AVAX TECHNOLOGIES, INC.
Date: July 26, 2000
By: /s/ David L. Tousley
---------------------------
Name: David L. Tousley
Title: Chief Financial Officer
3
<PAGE>
EXHIBIT INDEX
Exhibit Number Description
-------------- -----------
99.1 Press Release regarding commercialization
of M-Vax in Australia.
99.2 Press Release regarding Company's
agreement to acquire Genopoietic.
4
